Ghosh Priyanka E, Simopolous Thomas T
Beth Israel Deaconess Medical Center, Harvard Medical School, William Arnold-Carol A Warfield Pain Center Brookline, MA 02215, USA.
Pain Manag. 2019 May;9(3):225-231. doi: 10.2217/pmt-2018-0077. Epub 2019 Jan 30.
This article reviews Nevro Corporation's (CA, USA) Senza System high-frequency spinal cord stimulator (HF10 SCS). HF10 therapy has been shown to be noninferior to traditional low-frequency spinal cord stimulation (SCS), and in some studies, has been shown to have long-term effects that are superior compared with traditional low-frequency SCS in treating both back and leg pain. In addition, safety profiles for the HF10 SCS system were equivalent to traditional SCS. HF10 SCS is based on spinal anatomic mapping and does not require intraoperative paresthesia mapping for placement, thereby improving procedural experience for patients and reducing operating room time. HF10 SCS has altered the nature of SCS therapy in a manner that treats more individuals with chronic, refractory leg and back pain than in the past, and is widely used in the USA, Europe and Australia.
本文回顾了美国加利福尼亚州Nevro公司的Senza系统高频脊髓刺激器（HF10 SCS）。HF10疗法已被证明不劣于传统的低频脊髓刺激（SCS），并且在一些研究中，已显示出在治疗背部和腿部疼痛方面，其长期效果优于传统低频SCS。此外，HF10 SCS系统的安全性与传统SCS相当。HF10 SCS基于脊髓解剖图谱，放置时不需要术中感觉异常图谱，从而改善了患者的手术体验并减少了手术室时间。HF10 SCS改变了SCS疗法的性质，使比过去更多的慢性顽固性腿部和背部疼痛患者得到治疗，并且在美国、欧洲和澳大利亚广泛使用。
